OncoMatch/Clinical Trials/NCT07285850
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Is NCT07285850 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Sequential treatment of bevacizumab combined with atezolizumab (sequential group) and Simultaneous treatment of bevacizumab combined with atezolizumab (same period group) for hcc - hepatocellular carcinoma.
Treatment: Sequential treatment of bevacizumab combined with atezolizumab (sequential group) · Simultaneous treatment of bevacizumab combined with atezolizumab (same period group) — This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD). The study aims to compare the efficacy differences between sequential therapy and concurrent therapy using bevacizumab and atezolizumab for advanced HCC in MASLD. The research will focus on evaluating objective response rates, progression-free survival, disease control rates, and overall survival, while utilizing biomarker analysis to elucidate treatment mechanisms. Additionally, the study will examine treatment safety, including the incidence and severity of adverse events.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE C, BCLC STAGE D (BCLC)
Preoperative imaging diagnosis of advanced hepatocellular carcinoma (BCLC stage C or D, unsuitable for surgery)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: targeted therapy
Cannot have received: immunotherapy
Cannot have received: tace
Cannot have received: radiotherapy
Lab requirements
Blood counts
anc ≥ 1.5×10⁹/l, plt ≥ 100×10⁹/l, hb ≥ 90 g/l, no transfusion within 14 days
Kidney function
serum creatinine ≤ 1.5×uln, crcl ≥ 50 ml/min, urinary protein ≤ 1+ (or ≤1 g/24h if >1+)
Liver function
tbil ≤ 1.5×uln, ast/alt/alp ≤ 2.5×uln, alb ≥ 30 g/l, child-pugh a
Cardiac function
ecg normal or clinically insignificant, lvef > 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify